Healthcare Industry News:  Inflammatory Bowel Disease 

Biopharmaceuticals Gastroenterology

 News Release - May 11, 2012

Takeda Announces GEMINI II Trial of Vedolizumab in Patients with Moderately to Severely Active Crohn’s Disease Met Primary Endpoints of Improvement in Clinical Remission in Induction and Maintenance Phases

Patients in the trial had failed at least one conventional therapy

OSAKA, Japan--(Healthcare Sales & Marketing Network)--Takeda Pharmaceutical Company Limited (TSE:4502) today announced top-line results from the international, randomized, placebo-controlled, double-blind GEMINI II pivotal phase 3 trial. The trial evaluated vedolizumab in 1,115 patients with moderately to severely active Crohn’s disease who have failed at least one conventional therapy, including TNFa antagonists. Many of the patients included in the study had failed two or more TNFa antagonists. Patients received a year of vedolizumab (MLN0002) or placebo treatment, starting with six weeks of induction therapy. In both phases of the trial, induction and maintenance, vedolizumab demonstrated statistically significant improvement in the primary endpoint of clinical remission compared to placebo. Additionally, vedolizumab provided a numerically higher rate of enhanced response, the other primary end point in the induction phase, although not statistically significant.

The most common adverse events (>10 percent) reported in both the vedolizumab arm and the placebo arm were: Crohn’s disease, arthralgia(joint pain), pyrexia(fever), nasopharyngitis(upper respiratory inflammation), headache, nausea, and abdominal pain.

"People living with moderately to severely active Crohn’s disease currently have few treatment options to help them manage their disease,” said Asit Parikh, M.D., Ph.D., Vice President, General Medicine (Gastrointestinal and Genitourinary), Takeda. “We are very excited about the results of this pivotal study and the potential it may hold for patients.”

Detailed results will be presented at an upcoming medical congress.

About Vedolizumab

Vedolizumab is an investigational humanized monoclonal antibody against a4ß7 integrin, which is expressed on a subset of circulating white blood cells. These cells have been shown to play a role in mediating the inflammatory process in ulcerative colitis and Crohn’s disease.

About Crohn’s Disease

Crohn's disease is an Inflammatory Bowel Disease (IBD). It causes inflammation of the lining of the digestive tract, which can lead to abdominal pain, severe diarrhea and malnutrition. Inflammation caused by Crohn's disease can involve different areas of the digestive tract in different people. Crohn's disease can be both painful and debilitating, and sometimes may lead to life-threatening complications.

About Takeda

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website,

Source: Takeda Pharmaceutical

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.